N/A
N=10
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine
Prostate Cancer
Bottom Line
View on ClinicalTrials.gov: NCT02485964 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcome: Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Blood draw (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Male
- Sponsor
- University of Arkansas
- Primary completion
- Dec 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay |
4 | — |
Summary
To measure antigen-specific interferon-secretion by enzyme-linked immunospot (ELISPOT) assay, which measures antigen-specific interferon-secretion.
Eligibility Criteria
Inclusion Criteria
- Histological documented diagnosis of prostate cancer
- 18 years of age or older
- Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB)
Exclusion Criteria
- Subjects must have no other current malignancies.
- Subjects with prior history at any time of any basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration.
- Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration
Data sourced from ClinicalTrials.gov (NCT02485964). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.